Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SAT-3247 in Healthy Volunteers and DMD
NCT06565208Phase 1Completed
- Sponsor
- Satellos Bioscience Inc.
- Start
- Aug 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of forazapadin in Duchenne muscular dystrophy (DMD) (7 arms), sponsored by Satellos Bioscience Inc. Primary endpoint: Incidence and severity of treatment emergent adverse events. Started Aug 2024; status: completed.
02
Drugs
forazapadin
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT06565208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06565208.